Visiongain Publishes Acute Kidney Injury Treatment Market Report to 2031

10 March 2021

Visiongain has published a new report on Acute Kidney Injury Treatment Market Report to 2031: Forecasts By Product (Dialysis (Intermittent Hemodialysis, Continuous Renal Replacement Therapy (CRRT), Sustained low-efficiency Dialysis (SLED)), Drug Therapy (Antibiotics, Diuretics, and Immunosuppressive Agents) By Injury (Pre-renal Injury, Intrinsic Renal Injury, and Post-renal Injury), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, and Others) PLUS COVID-19 Recovery Scenarios.

Global Acute Kidney Injury Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on Acute Kidney Injury Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the acute kidney injury treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. In contrast, the rising research & development activities for developing novel treatments against COVID-19 is creating a lucrative opportunity for the companies. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

The Rising Prevalence of Acute Kidney Injury Among Population
The growth is mainly attributed to the rising geriatric population, the incidence of chronic disorders, and rising emergency department admissions, and the number of acute care admissions. for instance, The AKI incidence is assessed to be around 11.3 million annually. Out of which, approximately 1.7 million deaths are caused by Acute Kidney Injury worldwide annually. Around 1.4 million deaths happen in developing nations due to low income.

The U.S. Food and Drug Administration, government bodies, the European Medicines Agency, and the National Kidney Function took initiatives to develop novel clinical trials and treatment protocols. The U.S. Food and Drug Administration had approved a trial treatment Fast Track label to ASP1128 (Astellas Pharma), for people undergo coronary bypass and can develop moderate to severe AKI. Moreover, the stem cell therapy to treat acute kidney injury will create lucrative opportunities for the target industry growth. Continuous research & development and innovations in technology such as enhanced vascular access for hemodialysis and decreasing the consumption of the pill is expected to fuel the Acute Kidney Injury market growth.

Future Lies in Technology-Driven Acute Kidney Injury Treatment Devices
Traditional dialysis systems need manual modification of each parameter and human interference. With the help of robust technology at the center, key players operating in the industry must develop computerized, movable, and high tech dialysis machines to provide superior care to people of all age groups. This will able to set the disease parameter spontaneously and reduced the human error. Besides, the global key players are more focused to improve the efficacy of dialysis, with the usage of high-efficacy membranes, high-flux, and deriving from technical advances in membrane development and polymer chemistry.

Market Opportunities

Rapidly Increasing Health Care Expenditure
Healthcare spending has increased drastically in the U.S. in the past few decades. As per the Journal of the American Medical Association (JAMA), healthcare expenditure in the U.S. upsurge near a trillion dollars between 1996 and 2015. The association told that healthcare expenditure in the U.S. during 2017 was around $3.5 trillion, i. e, $11,000 per person. These expenditures are projected to be $6 trillion—approximately $17,000 per person by 2027.

Competitive Landscape
Key players operating in the target industry are Exponential Biotherapies, Inc., AM-Pharma, Asahi Kasei Medical Co., Ltd, AtoxBio, LG Chem Ltd., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Angion Biomedica Corp, Baxter International, Inc., NIKKISO AMERICA, INC., Thrasos Therapeutics Inc., RenalGuard Solutions, Inc., Quark Pharmaceuticals, Inc., and Sentien Biotechnologies, Inc.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Acute Kidney Injury Treatment market. For instance, on 29th April 2020, The U.S. Food and Drug Administration sanctioned CARPEDIEM System to Medtronic Inc. The new device design to offer uninterrupted hemodialysis or hemofiltration therapy to severely ill pediatric patients weighing between 5.5 to 22 pounds.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021


Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021


Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021


Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021